The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

May. 18, 2020
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Peter L. Collins, Silver Spring, MD (US);

Ursula J. Buchholz, Silver Spring, MD (US);

Cindy Luongo, Bethesda, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 39/155 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 39/12 (2013.01); A61K 39/155 (2013.01); C07K 14/005 (2013.01); A61K 2039/522 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/543 (2013.01); C12N 2760/18521 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18562 (2013.01);
Abstract

Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.


Find Patent Forward Citations

Loading…